116 related articles for article (PubMed ID: 25117814)
1. Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway.
Ghebeh H; Al-Khaldi S; Olabi S; Al-Dhfyan A; Al-Mohanna F; Barnawi R; Tulbah A; Al-Tweigeri T; Ajarim D; Al-Alwan M
Br J Cancer; 2014 Oct; 111(8):1552-61. PubMed ID: 25117814
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.
Christowitz C; Davis T; Isaacs A; van Niekerk G; Hattingh S; Engelbrecht AM
BMC Cancer; 2019 Aug; 19(1):757. PubMed ID: 31370818
[TBL] [Abstract][Full Text] [Related]
3. Fascin in migration and metastasis of breast cancer cells - A review.
Izdebska M; Zielińska W; Krajewski A; Grzanka A
Adv Med Sci; 2023 Sep; 68(2):290-297. PubMed ID: 37660543
[TBL] [Abstract][Full Text] [Related]
4. Biomechanical regulation of breast cancer metastasis and progression.
Spencer A; Sligar AD; Chavarria D; Lee J; Choksi D; Patil NP; Lee H; Veith AP; Riley WJ; Desai S; Abbaspour A; Singeetham R; Baker AB
Sci Rep; 2021 May; 11(1):9838. PubMed ID: 33972619
[TBL] [Abstract][Full Text] [Related]
5. The crucial role of fascin-1 in the pathogenesis, metastasis, and chemotherapeutic resistance of breast cancer.
Abdullah AR; Gamal El-Din AM; El-Mahdy HA; Ismail Y; El-Husseiny AA
Pathol Res Pract; 2024 Feb; 254():155079. PubMed ID: 38219494
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy promotes tumour cell hybridization in vivo.
Yan B; Wang J; Liu L
Tumour Biol; 2016 Apr; 37(4):5025-30. PubMed ID: 26537586
[TBL] [Abstract][Full Text] [Related]
7. ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Leccia F; Del Vecchio L; Mariotti E; Di Noto R; Morel AP; Puisieux A; Salvatore F; Ansieau S
Mol Cancer; 2014 Sep; 13():213. PubMed ID: 25216750
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
[TBL] [Abstract][Full Text] [Related]
9. Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer.
Min KW; Chae SW; Kim DH; DO SI; Kim K; Lee HJ; Sohn JH; Pyo JS; Kim DH; Oh S; Choi SH; Park YL; Park CH
Oncol Lett; 2015 Jul; 10(1):121-130. PubMed ID: 26170987
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway.
Maayah ZH; Ghebeh H; Alhaider AA; El-Kadi AO; Soshilov AA; Denison MS; Ansari MA; Korashy HM
Toxicol Appl Pharmacol; 2015 Apr; 284(2):217-26. PubMed ID: 25697376
[TBL] [Abstract][Full Text] [Related]
11. Fascin-1 as a biomarker and prospective therapeutic target in colorectal cancer.
Adams JC
Expert Rev Mol Diagn; 2015 Jan; 15(1):41-8. PubMed ID: 25370828
[TBL] [Abstract][Full Text] [Related]
12. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
[TBL] [Abstract][Full Text] [Related]
14. Pollutants, microbiota and immune system: frenemies within the gut.
Rio P; Gasbarrini A; Gambassi G; Cianci R
Front Public Health; 2024; 12():1285186. PubMed ID: 38799688
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel molecules and pathways associated with fascin actin‑bundling protein 1 in laryngeal squamous cell carcinoma through comprehensive transcriptome analysis.
Liu H; Hao W; Wang X; Zhang Y; He L; Xue X; Yang J; Zhang C
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426543
[TBL] [Abstract][Full Text] [Related]
16. Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial.
Asensi-Cantó A; Rodríguez-Braun E; Beltrán-Videla A; Hurtado AM; Conesa-Zamora P
Front Oncol; 2023; 13():1238464. PubMed ID: 37841433
[TBL] [Abstract][Full Text] [Related]
17. Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization.
Bai W; Ren JS; Xia M; Zhao Y; Ding JJ; Chen X; Jiang Q
J Transl Med; 2023 Aug; 21(1):555. PubMed ID: 37596693
[TBL] [Abstract][Full Text] [Related]
18. Fascin-1: Updated biological functions and therapeutic implications in cancer biology.
Li CH; Chan MH; Liang SM; Chang YC; Hsiao M
BBA Adv; 2022; 2():100052. PubMed ID: 37082587
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells.
Zeyn Y; Harms G; Tubbe I; Montermann E; Röhrig N; Hartmann M; Grabbe S; Bros M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681718
[TBL] [Abstract][Full Text] [Related]
20. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance.
Weiss F; Lauffenburger D; Friedl P
Nat Rev Cancer; 2022 Mar; 22(3):157-173. PubMed ID: 35013601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
